X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins (Alpha synuclein) implicated in neurodegeneration. It is being evaluated in phase 2 clinical trials for the treatment of multiple system atrophy.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, being developed in patients with early-stage multiple system atrophy, a rare neurodegenerative disease with no approved treatments.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, being developed in patients with early-stage multiple system atrophy, a rare neurodegenerative disease with no approved treatments.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration and new Phase 2 clinical trial of ATH434 in patients with Multiple System Atrophy (MSA) and the first patient has been enrolled.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
ATH434 is an oral agent designed to inhibit α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. It has excellent potential to treat Parkinson’s disease as well as Multiple System Atrophy (MSA).
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 (acyl hydrazone) in Alzheimer’s disease (AD).
Lead Product(s): PBT2
Therapeutic Area: Neurology Product Name: PBT2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Professor Colin Masters
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Details:
PBT2 is a low molecular weight drug candidate, orally bioavailable, crosses the blood-brain barrier, it has demonstrated efficacy in individuals with alzheimer’s disease.
Lead Product(s): PBT2
Therapeutic Area: Neurology Product Name: PBT2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
ATH434, is an oral agent which inhibits the aggregation of pathological proteins implicated in neurodegeneration disorders like MSA. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain.
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
